Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Value of susceptibility-weighted imaging in acute hemorrhagic leukoencephalitis.
[Progress of demyelinating animal models in the central nervous system].
AMPYRA® two-year safety data presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response.
[Interferon-β1b in multiple sclerosis therapy : More than 20 years clinical experience.]
[Possibilities of using the 2010 McDonald criteria for early diagnosis of multiple sclerosis.]
Transcranial direct current stimulation (tDCS) for fatigue in multiple sclerosis.
Future MS care: a consensus statement of the MS in the 21st Century Steering Group.
The effect of intravenous immunoglobulin on neuromyelitis optica.
A randomized clinical trial of valacyclovir in multiple sclerosis.
The Implication of Vitamin D and Autoimmunity: a Comprehensive Review.
Neuropathic pruritus (itch) in neuromyelitis optica.
MRI mean diffusivity detects widespread brain degeneration in multiple sclerosis.
Segmentation of Multiple Sclerosis Lesions in Brain MR Images Using Spatially Constrained Possibilistic Fuzzy C-Means Classification.
Investigation of the relationship between vitamin D and bone mineral density in newly diagnosed multiple sclerosis.
Charcot-Marie-Tooth Disease Type 4H Resulting from Compound Heterozygous Mutations in FGD4 from Nonconsanguineous Korean Families.
Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis.
Balance and Gait in People with Multiple Sclerosis: A Comparison with Healthy Controls and the Immediate Change after an Intervention based on the Bobath Concept.
Oral laquinimod for multiple sclerosis.
Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study.
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Scoring treatment response in patients with relapsing multiple sclerosis.
Severe dystonia as the first manifestation of neuromyelitis optica.
Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis.
Clinical Proton MR Spectroscopy in Central Nervous System Disorders.

Pages